Travel medicine interventions and neurological disease

Travel Medicine and Infectious Disease

Volumn 5, Issue 1, 2007, Pages 7-17

  Giovanetti, Franco ^a  

^a Azienda Sanitaria Locale Alba Bra   (Italy)

Author keywords

Antimalarials; Guillain Barr ; Immunization; Multiple sclerosis; Myasthenia

Indexed keywords

ANTIMALARIAL AGENT; BCG VACCINE; BETA INTERFERON; CHICKENPOX VACCINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; HEPATITIS A VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; METHOTREXATE; MITOXANTRONE; MUMPS VACCINE; ORAL POLIOMYELITIS VACCINE; PENICILLAMINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PREDNISONE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; TYPHOID VACCINE; UNINDEXED DRUG;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; FEASIBILITY STUDY; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION; MALARIA; MEDICAL CARE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; OPTIC NEURITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TRAVEL; VACCINATION;

GUILLAIN-BARRE SYNDROME; HUMANS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; RISK ASSESSMENT; TRAVEL;

EID: 33845188625     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2006.03.002     Document Type: Article

References (117)

1. World Tourism Organization. Tourism highlights. Madrid: WTO; 2005. Available at: http://www.world-tourism.org
2. Mermin J.H., Townes J.M., Gerber M., Dolan N., Mintz E.D., and Tauxe R.V. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 158 6 (1998) 633-638
3. Steffen R., and Connor B.A. Vaccines in travel health: from risk assessment to priorities. J Travel Med 12 1 (2005) 26-35
4. Wraith D.C., Goldman M., and Lambert P.H. Vaccination and autoimmune disease: what is the evidence? Lancet 362 9396 (2003) 1659-1666
5. McCoy L., Tsunoda I., and Fujinami R.S. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39 1 (2006) 9-19
6. Olson J.K., Croxford J.L., and Miller S.D. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 14 3 (2001) 227-250
7. Institute of Medicine. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders. Washington, DC: National Academy Press; 2002.
8. Schattner A., and Rager-Zisman B. Virus-induced autoimmunity. Rev Infect Dis 12 2 (1990) 204-222
9. Offit P.A., and Hackett C.J. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 111 3 (2003) 653-659
10. Jefferson T., Rudin M., and Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 4 2 (2004) 84-90
11. Satoh M., Kuroda Y., Yoshida H., Behney K.M., Mizutani A., Akaogi J., et al. Induction of lupus autoantibodies by adjuvants. J Autoimmun 21 1 (2003) 1-9
12. Frey S., Poland G., Percell S., and Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21 27-30 (2003) 4234-4237
13. World Health Organization. Causality assessment of adverse events following immunization. Wkly Epidemiol Record 76 (2001) 85-89
14. Atkinson W.L., Pickering L.K., Schwartz B., Weniger B.G., Iskander J.K., Watson J.C., et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 51 RR-2 (2002) 1-35
15. Arguin PM, Kozarsky PE, Navin AW. Yellow book: health information for international travel, 2005-2006. US Department of Health and Human Services: 2005. Available at: http://www.cdc.gov/travel/yb
16. Schwid S.R., Decker M.D., and Lopez-Bresnahan M. Rebif-Influenza Vaccine Study Investigators: immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 65 12 (2005) 1964-1966
17. Goldwater P.N. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 12 5 (1994) 410-414
18. Chlabicz S., Grzeszczuk A., and Lapinski T.W. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: the effect of interferon-alpha therapy. Med Sci Monit 8 5 (2002) CR379-CR383
19. Buljevac D., Flach H.Z., Hop W.C., Hijdra D., Laman J.D., Savelkoul H.F., et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125 Part 5 (2002) 952-960
20. Hughes R.A., and Cornblath D.R. Guillain-Barre syndrome. Lancet 366 9497 (2005) 1653-1666
21. Thomas C.E., Mayer S.A., Gungor Y., Swarup R., Webster E.A., Chang I., et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48 5 (1997) 1253-1260
22. Gout O. Vaccinations and multiple sclerosis. Neurol Sci 22 2 (2001) 151-154
23. Bakshi R., and Mazziotta J.C. Acute transverse myelitis after influenza vaccination: magnetic resonance imaging findings. J Neuroimag 6 4 (1996) 248-250
24. Hull T.P., and Bates J.H. Optic neuritis after influenza vaccination. Am J Ophthalmol 124 5 (1997) 703-704
25. Ray C.L., and Dreizin I.J. Bilateral optic neuropathy associated with influenza vaccination. J Neuroophthalmol 16 3 (1996) 182-184
26. Holt S., Hudgins D., Krishnan K.R., and Critchley E.M. Diffuse myelitis associated with rubella vaccination. Br Med J 2 6043 (1976) 1037-1038
27. Lim S., Park S.M., Choi H.S., Kim D.K., Kim H.B., Yang B.G., et al. Transverse myelitis after measles and rubella vaccination. J Paediatr Child Health 40 9-10 (2004) 583-584
28. Matsui M., Kawano H., Matsukura M., Otani Y., and Miike T. Acute transverse myelitis after Japanese B encephalitis vaccination in a 4-year-old girl. Brain Dev 24 3 (2002) 187-189
29. Kerrison J.B., Lounsbury D., Thirkill C.E., Lane R.G., Schatz M.P., and Engler R.M. Optic neuritis after anthrax vaccination. Ophthalmology 109 1 (2002) 99-104
30. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N Engl J Med 343 13 (2000) 938-952
31. Murray J. Infection as a cause of multiple sclerosis. Br Med J 325 (2002) 1128
32. Alotaibi S., Kennedy J., Tellier R., Stephens D., and Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 291 15 (2004) 1875-1879
33. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 61 10 (2004) 1613-1615
34. Sibley W.A., Bamford C.R., and Clark K. Clinical viral infections and multiple sclerosis. Lancet 1 (1985) 1313-1315
35. Fujinami R.S., von Herrath M.G., Christen U., and Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19 1 (2006) 80-94
36. Garg R.K. Acute disseminated encephalomyelitis. Postgrad Med J 79 927 (2003) 11-17
37. Dale R.C., de Sousa C., Chong W.K., Cox T.C., Harding B., and Neville B.G. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123 Part 12 (2000) 2407-2422
38. Kamei A., Ichinohe S., Onuma R., Hiraga S., and Fujiwara T. Acute disseminated demyelination due to primary human herpesvirus-6 infection. Eur J Pediatr 156 (1997) 709-712
39. David P., Baleriaux D., Bank W.O., Amrom D., De Temmerman D., Babusiaux C., et al. MRI of acute disseminated encephalomyelitis after coxsackie B infection. J Neuroradiol 20 (1993) 258-265
40. Silver B., McAvoy K., Mikesell S., and Smith T.W. Fulminating encephalopathy with perivenular demyelination and vacuolar myelopathy as the initial presentation of human immunodeficiency virus infection. Arch Neurol 54 (1997) 647-650
41. Nasralla C.A., Pay N., Goodpasture H.C., Lin J.J., and Svoboda W.B. Postinfectious encephalopathy in a child following Campylobacter jejuni enteritis. AJNR Am J Neuroradiol 14 2 (1993) 444-448
42. Ramachandran S., Wickremesinghe H.R., and Perera M.V. Acute disseminated encephalomyelitis in typhoid fever. Br Med J 1 (1975) 494-495
43. Tourbah A., Gout O., Liblau R., Lyon-Caen O., Bougniot C., Iba-Zizen M.T., et al. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?. Neurology 53 2 (1999) 396-401
44. Hynson J.L., Kornberg A.J., Coleman L.T., Shield L., Harvey A.S., and Kean M.J. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 56 10 (2001) 1308-1312
45. Gout O., and Lyon-Caen O. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol 154 (1998) 205-207
46. Tsai J.F., Margolis H.S., Jeng J.E., Ho M.S., Chang W.Y., Hsieh M.Y., et al. Immunoglobulin- and hepatitis B surface antigen-specific circulating immune complexes in chronic hepatitis B virus infection. Clin Immunol Immunopathol 86 3 (1998) 246-251
47. Han S.H. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 8 2 (2004) 403-418
48. Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial hepatitis B virus polymerase play a role through molecular mimicry?. Med Hypotheses 65 3 (2005) 509-520
49. Piaggio E., Ben Younes A., Desbois S., Gout O., Tourbah A., Lyon-Caen O., et al. Hepatitis B vaccination and central nervous system demyelination: an immunological approach. J Autoimmun 24 1 (2005) 33-37
50. Belloni C., Avanzini M.A., De Silvestri A., Martinetti M., Pasi A., Coslovich E., et al. No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine. Pediatrics 110 1 Part 1 (2002) e4
51. Institute of Medicine, Stratton KR, Alamario DA, Wizemann T, McCormick M, editors. Immunization safety review: influenza vaccines and neurological complications. Washington, DC: National Academy Press; 2004.
52. Ascherio A., Zhang S.M., Hernan M.A., Olek M.J., Coplan P.M., Brodovicz K., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344 5 (2001) 327-332
53. DeStefano F., Verstraeten T., Jackson L.A., Okoro C.A., Benson P., Black S.B., et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60 4 (2003) 504-509
54. Confavreux C., Suissa S., Saddier P., Bourdes V., and Vukusic S. Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 344 5 (2001) 319-326
55. Demicheli V., Rivetti A., Di Pietrantonj C., Clements C.J., and Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat 10 5 (2003) 343-344
56. Miller A.E., Morgante L.A., Buchwald L.Y., Nutile S.M., Coyle P.K., Krupp L.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48 2 (1997) 312-314
57. Moriabadi N.F., Niewiesk S., Kruse N., Jung S., Weissbrich B., ter Meulen V., et al. Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56 7 (2001) 938-943
58. Rutschmann O.T., McCrory D.C., and Matchar D.B. Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology 59 12 (2002) 1837-1843
59. Hernan M.A., Jick S.S., Olek M.J., and Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63 5 (2004) 838-842
60. World Health Organization Global Advisory Committee on Vaccine Safety. In: Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis" September 2004. Available at : http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en
61. Long G., and Rickman L. Infectious complications of tattoos. CID 18 (1994) 610-619
62. Correia J.D., Shafer R.T., Patel V., Kain K.C., Tessier D., MacPherson D., et al. Blood and body fluid exposure as a health risk for international travelers. J Travel Med 8 5 (2001) 263-266
63. Zuckerman J.N., and Steffen R. Risks of hepatitis B in travelers as compared to immunization status. J Travel Med 7 4 (2000) 170-174
64. Simonsen L., Kane A., Lloyd J., Zaffran M., and Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77 (1999) 789-800
65. Dijkstra J.A., Chappuis F., and Loutan L. Vaccine-preventable diseases in long-term expatriates. J Travel Med 12 Suppl 1 (2005) S47-S57
66. Freedman D.O., and Leder K. Influenza: changing approaches to prevention and treatment in travellers. J Travel Med 12 Suppl 1 (2005) 36-44
67. Jeffery D.R. The use of vaccinations in patients with multiple sclerosis. Infect Med 19 2 (2002) 73-79
68. Hughes R.A., and Cornblath D.R. Guillain-Barré syndrome. Lancet 366 9497 (2005) 1653-1666
69. Milner P., Lovelidge C.A., Taylor W.A., and Hughes R.A. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci 79 3 (1987) 275-285
70. Gabriel C.M., Hughes R.A., Moore S.E., Smith K.J., and Walsh F.S. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 121 Part 10 (1998) 1895-1902
71. Winer J.B., Hughes R.A., Anderson M.J., Jones D.M., Kangro H., and Watkins R.P. A prospective study of acute idiopathic neuropathy, II: antecedent events. J Neurol Neurosurg Psychiatr 51 5 (1988) 613-618
72. Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci 21 4 (2000) 229-234
73. Van Koningsveld R., Van Doorn P.A., Schmitz P.I., Ang C.W., and Van der Meche F.G. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54 3 (2000) 620-625
74. Hadden R.D., Karch H., Hartung H.P., Zielasek J., Weissbrich B., Schubert J., et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56 6 (2001) 758-765
75. Jacobs B.C., Rothbarth P.H., van der Meché F.G., Herbrink P., Schmitz P.I., de Klerk M.A., et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51 4 (1998) 1110-1115
76. Esack A., Teelucksingh S., and Singh N. The Guillain-Barré syndrome following dengue fever. West Indian Med J 48 (1999) 36-37
77. Langmuir A.D., Bregman D.J., Kurland L.T., Nathanson N., and Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119 6 (1984) 841-879
78. Hurwitz E.S., Schonberger L.B., Nelson D.B., and Holman R.C. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 304 26 (1981) 1557-1561
79. Kaplan J.E., Katona P., Hurwitz E.S., and Schonberger L.B. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. JAMA 248 6 (1982) 698-700
80. Chen R., Kent J., Rhodes P., Simon P., and Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barré Syndrome in the United States, 1990-91. Post Marketing Surveillance 6 (1992) 506
81. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 339 25 (1998) 1797-1802
82. Pollard J.D., and Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 37 1-2 (1978) 113-125
83. Galazka AM. The immunological basis for immunisation series: Module 3-Tetanus. WHO/EPI/GEN/98.13.1993. Geneva: World Health Organization;1993.
84. Blumenthal D., Prais D., Bron-Harlev E., and Amir J. Possible association of Guillain-Barre syndrome and hepatitis A vaccination. Pediatr Infect Dis J 23 6 (2004) 586-588
85. Shaw Jr. F.E., Graham D.J., Guess H.A., Milstien J.B., Johnson J.M., Schatz G.C., et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 127 2 (1988) 337-352
86. Siddiqui A., Usmani R.I., Anwer S., and Afsar S. Guillain-Barre syndrome occurring after rabies vaccination. J Pak Med Assoc 55 2 (2005) 87-88
87. Plotkin S.A., Rupprecht C.E., and Koprowski H. Rabies vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines, 3rd ed (1999), WB Saunders Company, Philadelphia 743-766
88. Rantala H., Cherry J.D., Shields W.D., and Uhari M. Epidemiology of Guillain-Barre syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 124 2 (1994) 220-223
89. Kinnunen E., Junttila O., Haukka J., and Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barre Syndrome. Am J Epidemiol 147 1 (1998) 69-73
90. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol 47 7 (1998) 563-567
91. Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1-21.
92. Centers for Disease Control and Prevention (CDC). Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June-July 2005. MMWR 2005;54(40):1023-5.
93. Food and Drug Administration. Meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (Menactra) [package insert]. Available at: http://www.fda.gov/cber/products/mpdtave011405.htm
94. Wijdicks E.F., Fletcher D.D., and Lawn N.D. Influenza vaccine and the risk of relapse of Guillain-Barre syndrome. Neurology 55 3 (2000) 452-453
95. Pritchard J., Mukherjee R., and Hughes R.A. Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatr 73 3 (2002) 348-349
96. Hughes R.A., Wijdicks E.F., Benson E., Cornblath D.R., Hahn A.F., Meythaler J.M., et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 62 8 (2005) 1194-1198
97. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Advisory Committee on Immunization Practices (ACIP), et al., Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54 (RR-8):1-40.
98. Bracebridge S., Crowcroft N., and White J. Tetanus immunisation policy in England and Wales-an overview of the literature. Commun Dis Public Health 7 4 (2004) 283-286
99. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181 Suppl 1 (2000) S2-S9
100. Anonymous. Diphtheria in visitors to Africa. Commun Dis Rep CDR Wkly 8 (1998) 289
101. Hill M. The neuromuscular junction disorders. J Neurol Neurosurg Psychiatr 74 (2003) ii32
102. Drachman D.B., et al. Myasthenia gravis and other diseases of the neuromuscular junction. In: Braunwald E., Fauci A.S., and Kasper D.L. (Eds). Harrison's principles of internal medicine, 15th ed (2001), McGraw-Hill, New York 2515-2520
103. Ballestero J.A., Plazas P.V., Kracun S., Gomez-Casati M.E., Taranda J., Rothlin C.V., et al. Effects of quinine, quinidine, and chloroquine on (alpha) 9 (alpha) 10 nicotinic cholinergic receptors. Mol Pharmacol 68 3 (2005) 822-829
104. Sieb J.P., Milone M., and Engel A.G. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Research 712 2 (1996) 179-189
105. Robberecht W., Bodnarik J., Bourgeois P., van Hees J., and Carton H. Myasthenic syndrome caused by a direct effect of chloroquine on neuromuscular transmission. Arch Neurol 46 (1989) 464-468
106. De Bleecker J., De Reuck J., and Quatacker J. Persistent chloroquine-induced myasthenia. Acta Clin Belg 46 (1991) 401-406
107. Sghirlanzoni A., Mantegazza R., Mora M., Pareyson D., and Cornelio F. Chloroquine myopathy and myasthenia-like syndrome. Muscle & Nerve 11 (1988) 114-119
108. Leger J.M., Puifoulloux H., Dancea S., Hauw J.J., Bouche P., Rougemont D., et al. Chloroquine neuromyopathies: 4 cases during antimalarial prevention. Rev Neurol 142 10 (1986) 746-752
109. Speich R., and Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med 331 1 (1994) 57-58
110. Fisher P.R., and Walker E. Myasthenia and malaria medicines. J Travel Med 9 (2002) 267-268
111. Durand J.M., Prince-Zucchelli M.A., Galland M.C., Pouget J., Harle J.R., Weiller P.J., et al. Syndrome myasthenique et doxycycline. Rev Med Intern 7 1 (1986) 68-69
112. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 9276 (2001) 98-104
113. Centers for Disease Control and Prevention (CDC). Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination 1996-2001. MMWR 2001;50 (30):643-5.
114. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR 51 RR-17 (2002) 1-11
115. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the yellow fever 17D vaccine. Vaccine 22 (2004) 2103-2105
116. Eidex R.B. History of thymoma and yellow fever vaccination. Lancet 364 (2004) 936
117. Taub D.D., and Longo D.L. Insights into thymic aging and regeneration. Immunol Rev 205 (2005) 72-93